Phosphorex and NOF CORPORATION Collaborate to Supply Lipid Nanoparticle Formulations using NOF's Proprietary Ionizable Lipid, COATSOME® SS Series
and TOKYO, April 30, 2024 /PRNewswire/ -- Phosphorex, an Ampersand Capital Partners company and drug delivery-focused contract development and manufacturing organization ("CDMO"), announced today a collaboration with NOF CORPORATION to supply its global clients with NOF's COATSOME® SS Series proprietary ionizable lipids, further enhancing its leading position in providing lipid nanoparticle (LNP)-based drug delivery solutions to the market.
- and TOKYO, April 30, 2024 /PRNewswire/ -- Phosphorex, an Ampersand Capital Partners company and drug delivery-focused contract development and manufacturing organization ("CDMO"), announced today a collaboration with NOF CORPORATION to supply its global clients with NOF's COATSOME® SS Series proprietary ionizable lipids, further enhancing its leading position in providing lipid nanoparticle (LNP)-based drug delivery solutions to the market.
- NOF CORPORATION's COATSOME® SS Series offers encapsulation of nucleic acids such as mRNA, siRNA, and pDNA.
- "This integrated approach, combining lipid chemistries with state-of-the-art development and manufacturing processes provides a well characterized platform for customers developing LNP-based therapies."
- With this collaboration NOF and Phosphorex create a highly specialized LNP-focused CDMO with unique capabilities," said Yuji Yamamoto, General Manager of Life Science division of NOF CORPORATION.